Cytox
Manchester
About Cytox
Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $15.5M
- Funding stage: Early Stage Venture
- Last round: Grant (Jan 2019)
- Website: cytoxgroup.com
- Phone: +441212024778
Industries & Categories
Biotechnology, Genetics
Social Profiles
Canonical: https://fsome.com/organization/cytox-121779 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.